$2.5M
Qualified
maximum offering price, as qualified
—
Reported Sold
no 1-K or 1-Z states a sold amount
2
Filings
across 1 offering
Equity Classes
| Type | Class | Outstanding | CUSIP | Publicly Traded |
|---|---|---|---|---|
| common | Common Equity | 451,738,971 | 90350U100 | OTC |
Service Providers
| Role | Provider |
|---|---|
| legal | Joseph I. Emas, Attorney at Law |
Offerings
| File Number | Filings | First Filed | Last Filed | Qualified | Price/Security | Securities Offered | Outstanding | Aggregate Offering | Supplements | Last Supplement |
|---|---|---|---|---|---|---|---|---|---|---|
| 024-11617 | 1 | 2021-08-30 | 2021-08-30 | 2021-09-10 | $0.01 | 250,000,000 | 456,217,501 | $2.5M | 1 | 2021-09-13 |
The statements and reported figures behind U.S. Stem Cell, Inc.
Operations, the balance sheet and cash flows as filed, year by year — the filer's own captions, not a mapped chart of accounts — plus the tagged figures from every Form 1-A family filing, plotted on the dates they were actually reported. EDGAR still has each 1-K; the dashboard lays every year they filed next to it.
- Every caption as the filer wrote it, across every annual report — not just the latest 1-K
- Tagged reported figures across every filing — revenue, assets, cash — with a sparkline on the actual filing dates
- A sparkline on each annual-statement line, so the shape is visible before the figures
- A revenue series dated to the filings that reported it
- A filing history that says what each document contributed, not only that it exists
- Follow it, and see it change on your watchlist
External link: SEC Filings